PDF(Pubmed)
Abstract：
Diabetic retinopathy (DR) is a major vision-threatening disease among the working-age population worldwide. Present therapeutic strategies such as intravitreal injection of anti-VEGF and laser photocoagulation mainly target proliferative DR. However, there is a need for early effective management in patients with early stage of DR before its progression into the more severe sight-threatening proliferative stage. Nutraceuticals, natural functional foods with few side effects, have been proposed to be beneficial in patients with DR. Over the decades, many studies, either in vitro or in vivo, have demonstrated the advantages of a number of nutraceuticals in DR with their antioxidative, anti-inflammatory, neuroprotective, or vasoprotective effects. However, only a few clinical trials have been conducted, and their outcomes varied. The low bioavailability and instability of many nutraceuticals have indeed hindered their utilization in clinical use. In this context, nanoparticle carriers have been developed to deliver nutraceuticals and to improve their bioavailability. Despite its preclinical nature, research of interventive nutraceuticals for DR may yield promising information in their clinical applications.
摘要：
糖尿病性视网膜病变（DR）是全球工作年龄人群中主要的视力威胁疾病。目前的治疗策略，例如玻璃体内注射抗VEGF和激光光凝主要靶向增殖DR。然而,在DR进展到更严重的危及视力的增生期之前,需要对早期DR患者进行早期有效的治疗.营养食品,几乎没有副作用的天然功能食品，有人提出对DR患者有益。几十年来,许多研究,在体外或体内，已经证明了许多营养保健品在DR中的优势，抗炎,神经保护,或血管保护作用。然而,只进行了一些临床试验，他们的结果各不相同。许多营养品的低生物利用度和不稳定性确实阻碍了它们在临床应用中的利用。在这种情况下，已经开发了纳米颗粒载体来递送营养品并提高其生物利用度。尽管具有临床前性质，对DR的干预性营养药物的研究可能会在其临床应用中产生有希望的信息。
